11 News & Press Releases found
Araris Biotech AG News
-
Araris Biotech AG Appoints Filippo Mulinacci, Ph.D., MBA as Chief Business Officer
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, is pleased to announce the appointment of Filippo Mulinacci, Ph.D., MBA as chief business officer. “We are thrilled to welcome Filippo to ...
-
Araris Biotech appoints Bernd Schlereth as Chief Development Officer
Araris Biotech AG, a company pioneering antibody-drug conjugate (ADC)-linker technology, announced today that it has recruited Dr. Bernd Schlereth as Chief Development Officer (CDO). He brings with him more than 20 years of experience in ...
-
Araris Biotech Closes $24 Million Financing Round
Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the closing of a $24 million financing round, bringing the total funds raised ...
-
Araris Biotech AG to Present at Informa Connect’s Next Generation Protein Therapeutics Summit
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the company’s chief executive officer, Philipp Spycher, Ph.D., will be a speaker at the Next Generation Protein Therapeutics ...
-
Araris Biotech AG to Present at 13th Annual World ADC San Diego 2022
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that the company will present data on Araris’ linker technology at the 13th Annual World ADC Conference in San Diego. The ...
-
Araris Biotech AG to Present at the H.C. Wainwright Preclinical Cancer Drug Discovery Virtual Conference
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the company will be presenting at the H.C. Wainwright Preclinical Cancer Drug Discovery: Emerging Targets and Modalities virtual ...
-
Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting
Araris Biotech AG, a company pioneering a proprietary antibodydrug conjugate (ADC)-linker technology, today announced the company will deliver a poster presentation and an oral presentation at this year’s American Association for Cancer ...
-
Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting
Araris Biotech AG, a company pioneering a proprietary antibodydrug conjugate (ADC)-linker technology, today announced the company will deliver a poster presentation and an oral presentation at this year’s American Association for Cancer ...
-
Araris Biotech AG to Present at 12th Annual World ADC London 2022
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that Philipp Probst, Ph.D., Associate Director of ADC Research at Araris, will present data on the company’s linker ...
-
Araris Biotech AG to Present at 12th Annual World ADC London 2022
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced that Philipp Probst, Ph.D., Associate Director of ADC Research at Araris, will present data on the company’s linker ...
-
Araris Biotech AG Expands Scientific Advisory Board with Appointment of Dr. Jeff Sharman and Dr. Clive Stanway
Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, announced that the company is expanding its scientific advisory board with the appointment of Jeff Sharman, M.D. and Clive Stanway, Ph.D. These ...